Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)

China flag China · Delayed Price · Currency is CNY
9.81
-0.15 (-1.51%)
At close: Feb 13, 2026
Market Cap16.35B +18.7%
Revenue (ttm)2.58B -6.8%
Net Income668.71M -14.5%
EPS0.40 -13.8%
Shares Out1.67B
PE Ratio24.42
Forward PEn/a
Dividend0.30 (3.01%)
Ex-Dividend Daten/a
Volume16,495,200
Average Volume22,645,609
Open9.92
Previous Close9.96
Day's Range9.80 - 9.99
52-Week Range7.38 - 13.06
Beta0.57
RSI41.16
Earnings DateMar 31, 2026

About SHE:300009

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life det... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 2,647
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300009
Full Company Profile

Financial Performance

In 2024, SHE:300009's revenue was 2.54 billion, a decrease of -11.51% compared to the previous year's 2.87 billion. Earnings were 706.95 million, a decrease of -16.56%.

Financial Statements